AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | n/a |
Market Cap | 888 |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -7.61 |
PE Ratio (ttm) | 0 |
Forward PE | n/a |
Analyst | Buy |
Ask | n/a |
Volume | 140 |
Avg. Volume (20D) | 99 |
Open | 0.00 |
Previous Close | undefined |
Day's Range | 0.00 - 0.00 |
52-Week Range | 0.00 - 1.08 |
Beta | undefined |
About UTRS
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bl...
Analyst Forecast
According to 1 analyst ratings, the average rating for UTRS stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.